Clinical trials
Pulmonary Hypertension Due to Lung Diseases and Hypoxia clinical trials
Below are recruiting pulmonary hypertension due to lung diseases and hypoxia clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Birmingham, AlabamaAges 18 years+ - NCT04467333Recruiting
Registry for lung cancer patients at a pulmonary hypertension center
This is a hospital registry study that collects information from people with lung cancer. It looks at pulmonary hypertension (high blood pressure in the lungs) in relation to lung cancer, which may help doctors understand risk and care needs.
Giessen, HesseAges 18 years+ - NCT07147114RecruitingPhase 4
Combined macitentan and dapagliflozin for heart failure with lung high blood pressure
This trial tests whether adding two medications—macitentan and dapagliflozin—together is safe and effective for people with heart failure and a certain type of high blood pressure in the lungs. It might help improve your symptoms and daily function.
BusanAges 19 years+ - NCT04808596Recruiting
Pulmonary hypertension registry and blood sample study
This study builds a registry and collection system for people with pulmonary hypertension, confirmed by a specific heart test. By joining, you help researchers learn more about the condition and may support future studies.
Kansas City, KansasAges 18 years+ - NCT05798923RecruitingPhase 2
LAM-001 for lung scarring with high blood pressure
This trial tests a new medication called LAM-001 for people with high blood pressure in the lungs caused by lung scarring. It aims to see if it can improve symptoms and help you feel better.
Tucson, ArizonaAges 18–80 - NCT05937854RecruitingPhase 2
Tadalafil to help breathing in COPD with pulmonary hypertension
This Phase 2 study tests whether tadalafil can improve breathlessness in people with COPD and pulmonary hypertension (high blood pressure in the lungs). It may help you breathe more easily if your symptoms are driven by this specific lung circulation problem.
Aurora, ColoradoAges 35–89 - NCT06336798RecruitingPhase 2
Pioglitazone for pulmonary hypertension from lung disease
This trial tests if pioglitazone, a medicine used for diabetes, can help people with high blood pressure in their lungs caused by chronic lung disease. The goal is to see if it improves how your cells use energy.
Atlanta, GeorgiaAges 18 years+ - NCT06512935Recruiting
Ventilator study for preterm infants with lung recovery
This study tests a new way of setting the ventilator for preterm babies born before 34 weeks who are still on a breathing machine. It aims to improve lung healing and heart function by finding the best pressure settings. The results could help your baby breathe more comfortably.
Birmingham, AlabamaAges 1 week–4 weeks - NCT07318597RecruitingPhase 2
A study of an experimental drug for pulmonary arterial hypertension
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Aurora, ColoradoAges 18 years+ - NCT07487727RecruitingPhase 3
Study of an experimental anemia drug for chronic kidney disease patients not on dialysis
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06968962Recruiting
Starting PAH treatment: one drug first or two drugs together?
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
Hangzhou, ZhejiangAges 18–80
Hear when a new Pulmonary Hypertension Due to Lung Diseases and Hypoxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary hypertension due to lung diseases and hypoxia?
- Yes. Clin2 currently lists 11 recruiting pulmonary hypertension due to lung diseases and hypoxia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary hypertension due to lung diseases and hypoxia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary hypertension due to lung diseases and hypoxia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.